@article{3c676ae6b4744fe3a8d0b41201e5a86f,
title = "Case report: Salvage capmatinib therapy in KIF5B-MET fusion-positive lung adenocarcinoma with resistance to telisotuzumab vedotin",
abstract = "Telisotuzumab vedotin is a MET-targeting antibody–drug conjugate that has demonstrated a good treatment response in patients with EGFR wild-type MET-overexpressing non-squamous non-small cell lung cancer. However, patients have been reported to acquire resistance to this drug, and the subsequent therapy has not been standardized. Here, we present a case of a 56-year-old woman diagnosed with KIF5B-MET fusion-positive non-small cell lung cancer who had a durable response to capmatinib after acquired resistance to telisotuzumab vedotin.",
author = "Lin, {Chien Yu} and Wei, {Sheng Huan} and Chen, {Yi Lin} and Lee, {Chung Ta} and Wu, {Shang Yin} and Ho, {Chung Liang} and Pavlick, {Dean C.} and Su, {Po Lan} and Lin, {Chien Chung}",
note = "Funding Information: The present study was funded by grant no. MOST 110-2314-B-006-102, MOST 111-2314-B-006 -092-MY3 from the Ministry of Science and Technology, Taiwan, and grant no. NCKUH-11102019 from National Cheng Kung University Hospital, Taiwan. Publisher Copyright: Copyright {\textcopyright} 2022 Lin, Wei, Chen, Lee, Wu, Ho, Pavlick, Su and Lin.",
year = "2022",
month = aug,
day = "11",
doi = "10.3389/fonc.2022.919123",
language = "English",
volume = "12",
journal = "Frontiers in Oncology",
issn = "2234-943X",
publisher = "Frontiers Media S. A.",
}